The Wayne, Penn.-based company’s CleanSweep system uses both balloon sweeping tech and traditional suction collection to remove secretion build-up on the insides of endotracheal tubes. In early bench top testing the system was shown to remove 2.5 times more secretions than leading, traditional closed suction devices, the company said.
“Evaluating the effectiveness of closed suction devices further supports Teleflex’s commitment to developing technologies that help to advance respiratory care. CleanSweep closed suction system has the potential to make a positive impact to airway management of the critical care patient,” Teleflex respiratory VP Michael DiGiuseppe said in a press release.
The trial will take place at Durham, N.C.’s Duke University Hospital, Teleflex said, and will explore the system’s ability to treat patients who are receiving pressure or volume assist control ventilation who require endotracheal tube suctioning more frequently than once every 2.5 hours.
Patients will be randomized to treatment with the CleanSweep system or standard closed suctioning. Prior to suctioning and within 15 minutes after research investigators will measure respiratory system mechanics, hemodynamics and gas exchange, Teleflex said.
“During mechanical ventilation, secretions accumulate and microbial biofilm may form inside the ET tube. Even small reductions in ET tube radius can increase airflow resistance significantly. The CleanSweep closed suction system may offer significant advantages in reducing ET tube obstruction,” Dr. Neil MacIntyre of Duke University Hospital said in a prepared statement.
Earlier this month, Teleflex saw shares fall after the medical device maker beat earnings per share expectations on Wall Street but missed on sales consensus with its second quarter results.